Variations of Immune Infiltrate and Cell Plasticity Markers in Treated Metastatic Melanoma Patients

Inclusion criteria

• Patient age ≥ 18
• Female patients must agree to the use of 2 methods of contraception. For man one method of contraception is needed if if his partner is in childbearing age throughout the study and for at least 5 months after last study treatment administration.
• Patients with metastatic stage III or IV melanoma relapse
• Eligible for a melanoma metastatic treatment indicated and administered as part of usual care
• Patients must be willing and able to undergo cutaneous tumor biopsies (except on the face and folds or lymph node) according to the study protocol
• Patient insured or beneficiary of a health insurance plan
• Patient able to provide informed consent and sign approved consent forms to participate in the study
• Patient accepting the conservation of biological samples and their use for clinical research including genetic research

Exclusion criteria

• Hematologic tumours under treatment
• Patients with a documented history of autoimmune pathology
• Ocular melanoma
• Persons placed under the safeguard of justice
• Use of immunosuppressants including corticosteroids 4 weeks before the inclusion